-
Bifendate (DDB) for Hepatic Lipid Research
2026-09-25
Use Bifendate (DDB) to test changes in liver lipid burden separately from circulating lipid levels—a distinction supported by diet-induced mouse models. This practical guide connects dose selection, compound handling, and paired lipid and autophagy readouts to help researchers build interpretable liver studies.
-
BAY-826 and the Neurovascular Logic of Retinal Survival
2026-09-25
Angiopoietin signaling in Müller cells can influence retinal neuron survival through Tie-2/PI3K/Akt activity and PEDF. This article explains what that mechanism means for translational assay design, where BAY-826 may fit as a research tool, and why pathway relevance must not be mistaken for proof of the compound’s target or cellular effect.
-
Calpain Inhibitor I, ALLN: Practical Research Guide
2026-09-24
Calpain Inhibitor I, ALLN (SKU A2602) provides a way to inhibit calpains and selected cathepsins when studying protease activity, apoptosis, or injury-associated responses. It is intended for research workflows, not diagnostic or clinical use; its water insolubility and activity against multiple cysteine proteases require careful vehicle controls and interpretation.
-
Ziprasidone HCl: Workflows for Neuroscience and Cancer
2026-09-24
Ziprasidone HCl connects receptor-focused neuroscience research with preclinical studies of GOT1 and tumor-cell metabolism, but each use requires its own controls and interpretation. This practical guide covers setup, assay planning, reported benchmarks, and troubleshooting without treating laboratory findings as evidence of clinical anticancer benefit.
-
Angiotensin I: Applied Research Workflows
2026-09-23
Angiotensin I provides a practical upstream substrate for renin-angiotensin system research, ACE conversion assays, cardiovascular disease mechanisms, and antihypertensive drug screening. This guide connects peptide handling with translational workflows while clarifying how recent spike-protein binding findings should—and should not—influence assay design.
-
2-NBDG: Practical Glucose Uptake Assay Guide
2026-09-22
2-NBDG is a fluorescent cellular glucose uptake tracer for comparing glucose transport and intracellular probe accumulation by flow cytometry, microscopy, or plate-based assays. It is suitable for controlled research workflows, but it should not be interpreted as a direct measurement of glycolytic flux, clinical glucose handling, or pathway activity without orthogonal validation.
-
Cholesterol as a Variable in mRNA-LNP Assays
2026-09-22
Cholesterol is more than a structural lipid in mRNA-LNP research: it can become an experimental variable that shapes particle behavior and assay interpretation. This article connects B1702 handling with insights from localized p21 mRNA delivery in bladder cancer while defining the controls needed for defensible conclusions.
-
3D Osteocyte Networks under Pulsatile Fluid Flow
2026-09-21
The 2025 ACS Biomaterials Science & Engineering study introduces a transparent, three-dimensional microfluidic model for exposing collagen-embedded MLO-Y4 osteocyte networks to pulsatile unidirectional fluid flow. Its results show that defined flow frequencies trigger calcium signals that propagate through connexin 43-dependent cell connections while osteocyte phenotypes remain measurable during extended culture.
-
CD44 Metabolic Rewiring in IDH-Mutant Leukemia
2026-09-21
The reference study identifies CD44 as a metabolic dependency in IDH-mutant leukemia, linking adhesion signaling to pentose phosphate activity, NADPH production, and sustained R-2HG synthesis. Its isogenic genetic models and combination experiments suggest that disrupting CD44-mediated rewiring may complement mutant IDH inhibition, although clinical translation remains to be established.
-
Sodium Picosulfate in Gut–Brain Assay Design
2026-09-20
Sodium Picosulfate can do more than model constipation: it can help researchers separate intestinal transit effects from regional neuroinflammation signals. This article connects B2027 reagent design with [18F]PBR146 imaging in chronic hepatic encephalopathy while defining the limits of current evidence.
-
RRP Restores Lipid Metabolism in Hepatic IRI
2026-09-19
A 2024 Journal of Ethnopharmacology study shows that Radix Rehmanniae Praeparata extracts reduce hepatic ischemia-reperfusion injury by correcting hepatocyte cholesterol handling, rather than acting only as a general hepatoprotective treatment. Its key mechanistic contribution is an AMPK–mTOR-centered pathway that suppresses SCAP–SREBP2 cholesterol synthesis while promoting LXRα-dependent cholesterol efflux.
-
Thiamet G: O-GlcNAcase Inhibitor Workflows
2026-09-19
Thiamet G provides a controlled way to raise protein O-GlcNAcylation in neuronal, leukemia, differentiation, and emerging placental stress assays. This guide connects concentration design, orthogonal readouts, tau and ferroptosis workflows, and troubleshooting to the HUWE1–TfR1 mechanism reported in preeclampsia research.
-
AG-120 (Ivosidenib) IDH1 Research Workflows
2026-09-18
AG-120 (Ivosidenib) enables a practical mutant-IDH1 workflow that connects 2-hydroxyglutarate reduction with differentiation phenotypes in AML models. This guide combines dosing, metabolite analysis, CD44-aware assay design, and troubleshooting for more interpretable results.
-
Triacetin Digestion and Hepatic Metabolic Signaling
2026-09-17
A 2025 rat study shows that triacetin is completely degraded in the upper gastrointestinal tract and absorbed mainly as acetate and glycerol rather than reaching the colon intact. The findings connect short-chain triacylglycerol digestion with hepatic AMPK activation, altered lipid-related gene expression, and a broader substrate-plus-signal model of nutrient metabolism.
-
BCLAF1–YTHDF2–SIX1 Axis in ESCC Progression
2026-09-17
The reference study identifies a BCLAF1–YTHDF2–SIX1 regulatory axis that connects m⁶A-dependent RNA turnover with glycolysis and malignant behavior in esophageal squamous cell carcinoma. Its integration of protein-interaction assays, MeRIP-seq, RIP-seq, transcriptomics, functional studies, and in vivo validation provides a mechanistic framework for interpreting BCLAF1 as a regulator of RNA fate rather than only a transcription-associated factor.